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DOES INHALED NITRIC OXIDE SUPPRESS ENDOGENOUS NITRIC OXIDE PRODUCTION?  
Allan P. Goldman, MRCP, S. G. Haworth, FRCP, and D. J. Macrae, FRCA, London, United Kingdom 
Inhaled nitric oxide (INO) has emerged as a promis- 
ing selective pulmonary vasodilator for children with 
corrected ~and uncorrected 2 congenital heart defects. 
We and others 3 have noticed, however, that some 
patients become extremely dependent on this therapy 
during the first few days of its administration, so that 
sudden discontinuation of INO at this point in time 
causes marked instability. We hypothesize that this 
effect may be due in part to exogenous INO suppressing 
or down-regulating endogenous nitrous oxide (NO) 
production by the pulmonary endothelium. Cyclic 
guanosine monophosphate (cGMP) is the final messen- 
ger of the L-arginine nitric oxide pathway. It was 
postulated that if INO were suppressing endogenous 
NO production during its early administration, the 
cyclic cGMP levels would then progressively fall if the 
INO was discontinued uring this period. 
A 2-month-old, 3.8 kg male infant with supracardiac 
total anomalous pulmonary venous drainage had recur- 
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rent pulmonary hypertensive crises during the 5 days 
after complete surgical correction. During these crises, 
there was an acute rise in pulmonary arterial pressure 
to suprasystemic levels; this rise could only be controlled 
with high-pressure hand-bag ventilation with 100% oxygen. 
These crises did not abate with ma_~aal conventional ther- 
apy, including mechanical ventilation, alkalinization, seda- 
tion and neuromuscular blockade, intravenous vasodilators 
(nitroglycerine at 7/zg • kg -1 • min-1), and inotropic sup- 
port (dopamine at 8 k~g " kg  -1  " min-1). Cardiac catheter- 
ization at this time revealed good hemodynamics, with no 
evidence of obstructed pulmonary venous flow (right pulmo- 
nary capillary wedge pressure 12 mm Hg, left pulmonary 
capillary wedge pressure 12 mm Hg, left ventricular end- 
diastolic pressure 13 mm Hg), suggesting that the cause of 
the pulmonary hypertension was a reactive pulmonary vas- 
culature rather than mechanical obstruction. The patient was 
given a trial of 20 ppm INO as part of ongoing investigational 
NO studies at our institution. Blood samples for cGMP 
levels were withdrawn daily from the indwelling arterial 
catheter both with and without INO. Daily reverse dose- 
response studies were conducted to allow INO to be reduced 
gradually as clinical improvement progressed. This entailed 
gradually reducing the dose of INO in i to 2 ppm aliquots as 
clinically tolerated. The blood samples were immediately 
placed on ice and spun at 3000 rpm at 4 ° C for 10 minutes. 
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Fig. 1. Concentration of cGMP and ratio of pulmonary arterial pressure (PAP) to systemic arterial 
pressure (SAP). 
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were measured by radioimmunoassay (Amersham RPA525; 
Amersham International Ltd., Little Chalfont, U.K.). Arte- 
rial cGMP concentrations and the mean pulmonary arterial- 
systemic arterial pressure ratios, recorded with and without 
INO, are shown in Fig. 1. 
Our results show that although the cGMP concentra- 
tions increased with the commencement of INO, levels 
appeared to fall below baseline when attempts were 
made to wean the patient from INO during the first 6 
days of its administration. After 6 days of INO therapy, 
discontinuation of the INO was no longer associated 
with a fall in cGMP concentrations; this coincided with 
clinical resolution of the pulmonary hypertension, sug- 
gesting that spontaneous recovery of endogenous NO 
production had occurred. The patient was extubated 1
day later and was discharged home after 4 more days. 
We believe that these results support he hypothesis 
that exogenous INO suppresses endogenous NO pro- 
duction after cardiopulmonary bypass when known 
reversible endothelial damage has occurred. 4 Exoge- 
nous NO has been shown to suppress endogenous NO 
production in the rat cerebellum by inhibiting nitric 
oxide synthetase, the rate-limiting enzyme of NO pro- 
duction. 5Our findings indicate that similar changes may 
be occuring in the pulmonary endothelium. An alterna- 
tive explanation could be that the falling concentrations 
of cGMP are the result of disease of the pulmonary 
endothelium, which is ongoing and was itself the initial 
cause of the pulmonary hypertension. 
In conclusion, exogenous INO may suppress endog- 
enous NO production by the pulmonary endothelium 
during the early course of its administration. This has a 
number of important clinical implications. First, regular 
reverse dose-response studies should be conducted to 
allow the patient o be gradually weaned from INO as 
clinical improvement and endothelial recovery 
progress, because rebound pulmonary hypertension 
may occur if INO treatment is discontinued abruptly. 
Second, patients already receiving INO who require 
transfer to tertiary centers may require the INO admin- 
istration to be continued uring the transport. Finally, 
although prophylactic INO administration may be con- 
sidered in patients at high risk, its administration may 
lengthen the time required for mechanical ventilation. 
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EVANS BLUE AND GENTIAN VIOLET: ALTERNATIVES TO METHYLENE BLUE AS A SURGICAL 
MARKER DYE 
Kanili Shoemaker, a Joseph Rubin, MD, b G. Lionel Zumbro, MD, c and Randall Tackett, PhD, a 
Athens and Augusta, Ga. 
Dyes, such as methylene blue, are used during vascular 
surgery to aid in the visualization and orientation of the 
blood vessel. Although methylene blue dye is believed to 
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be innocuous, we I recently demonstrated that extravascu- 
lar application of 1% methylene blue impairs both endo- 
thelium-dependent a d endothelium-independent vasore- 
laxation. The present study investigated Evans blue and 
gentian violet as alternative surgical marker dyes to 
methylene blue. 
Human saphenous veins were cut into 2 to 4 mm rings, 
carefully swabbed with 0.5% Evans blue, 1.0% gentian 
violet, or Krebs buffer, and incubated in 20 ml of buffer at 
25 ° C for 45 minutes. The vascular ings were then sus- 
pended in 10 ml tissue baths containing Krebs buffer, and 
dose-response curves to acetylcholine, isoproterenol, ve 
rapamil, and sodium nitroprusside were performed as 
previously described. 1 
Vascular ings were assayed in duplicate and averaged 
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